Postmarketing surveillance for drug abuse.

Postmarketing surveillance for drug abuse.

Item
http://www.wikidata.org/entity/Q35132192
Subjective and objective effects of the novel triple reuptake inhibitor tesofensine in recreational stimulant usersAbuse liability assessment of tobacco products including potential reduced exposure productsIndicators of drug-seeking aberrant behaviours: the feasibility of use in observational post-marketing cohort studies for risk managementDeterminants of fentanyl and other potent µ opioid agonist misuse in opioid-dependent individuals.Factors associated with the transition from abuse to dependence among substance abusers: implications for a measure of addictive liability.Measures to quantify the abuse of prescription opioids: a review of data sources and metrics.Abuse risks and routes of administration of different prescription opioid compounds and formulations.The use and potential abuse of anticholinergic antiparkinson drugs in Norway: a pharmacoepidemiological study.
P2860

Postmarketing surveillance for drug abuse.

Item
http://www.wikidata.org/entity/Q35132192
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Postmarketing surveillance for drug abuse.
@ast
Postmarketing surveillance for drug abuse.
@en
type
label
Postmarketing surveillance for drug abuse.
@ast
Postmarketing surveillance for drug abuse.
@en
prefLabel
Postmarketing surveillance for drug abuse.
@ast
Postmarketing surveillance for drug abuse.
@en
P1433
P1476
P2093
P304
P31
P356
P433
P478
P577
P5875
P698
P356
P1433
P1476
Postmarketing surveillance for drug abuse.
@en
P2093
P304
P31
P356
10.1016/S0376-8716(03)00102-9
P433
P478
P577
P5875
P698